Loading…
Infliximab in the treatment of patients with Crohn's disease: preliminary report
Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn's disease. Infliximab, a monoclonal antibody against tumor necrosis factor, is useful in the treatment of Crohn's disease, specially when the disease is active and associated to fistula formation. To assess th...
Saved in:
Published in: | Revista medíca de Chile 2006-03, Vol.134 (3), p.320-325 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | Spanish |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 325 |
container_issue | 3 |
container_start_page | 320 |
container_title | Revista medíca de Chile |
container_volume | 134 |
creator | Gellona V, José Zarraonandia A, Antón Zúñiga D, Alvaro Palma C, Renato Contreras P, Jaime Silva Ch, Jaime González D, Róbinson Quintana V, Carlos |
description | Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn's disease. Infliximab, a monoclonal antibody against tumor necrosis factor, is useful in the treatment of Crohn's disease, specially when the disease is active and associated to fistula formation.
To assess the effectiveness of Infliximab in patients with Crohn's disease.
Twelve patients with Crohn's disease (aged 16 to 63 years, 10 women) refractory to treatment with steroid, 5-aminosalicylic acid, antimicrobials and immunomodulatory drugs, were studied. A single intravenous 5 mg/kg dose Infliximab was administered. The Crohn's disease activity index (CDAI) was measured before and one week after the administration of the drug.
CDAI before and after Infliximab administration was 357+/-62 and 138+/-122 score points, respectively (p |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_67941142</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67941142</sourcerecordid><originalsourceid>FETCH-LOGICAL-p139t-8d5a2cf0af421a5a999009245a5b252dfe2c0b8ab78593f649dc1cff50dcb6ac3</originalsourceid><addsrcrecordid>eNo1kM1KxDAYRbNQnHH0FSQrXRWSNGkbd1L8GRjQha7L1_QLjfQnJik6b2_BcXXP4nDh3jOyZSyXma6qckMuY_xkTJQFry7IhhfFSkxuydt-soP7cSO01E009UhTQEgjTonOlnpIbsVIv13qaR3mfrqLtHMRIeI99QEHN7oJwpEG9HNIV-TcwhDx-pQ78vH0-F6_ZIfX5339cMg8z3XKqk6BMJaBlYKDAq01Y1pIBaoVSnQWhWFtBW1ZKZ3bQurOcGOtYp1pCzD5jtz-9fowfy0YUzO6aHAYYMJ5iU1Rasm5FKt4cxKXdsSu8WEdG47N_wf5LzecWGY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67941142</pqid></control><display><type>article</type><title>Infliximab in the treatment of patients with Crohn's disease: preliminary report</title><source>SciELO</source><creator>Gellona V, José ; Zarraonandia A, Antón ; Zúñiga D, Alvaro ; Palma C, Renato ; Contreras P, Jaime ; Silva Ch, Jaime ; González D, Róbinson ; Quintana V, Carlos</creator><creatorcontrib>Gellona V, José ; Zarraonandia A, Antón ; Zúñiga D, Alvaro ; Palma C, Renato ; Contreras P, Jaime ; Silva Ch, Jaime ; González D, Róbinson ; Quintana V, Carlos</creatorcontrib><description>Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn's disease. Infliximab, a monoclonal antibody against tumor necrosis factor, is useful in the treatment of Crohn's disease, specially when the disease is active and associated to fistula formation.
To assess the effectiveness of Infliximab in patients with Crohn's disease.
Twelve patients with Crohn's disease (aged 16 to 63 years, 10 women) refractory to treatment with steroid, 5-aminosalicylic acid, antimicrobials and immunomodulatory drugs, were studied. A single intravenous 5 mg/kg dose Infliximab was administered. The Crohn's disease activity index (CDAI) was measured before and one week after the administration of the drug.
CDAI before and after Infliximab administration was 357+/-62 and 138+/-122 score points, respectively (p <0.005). According to this score, five patients had a severe and seven a moderate disease flare. The disease remitted in 7 (58%) and a clinical response was observed in 75%.
A single dose of Infliximab was effective to induce remission of the disease in 75% of this selected group of patients with Crohn's disease.</description><identifier>ISSN: 0034-9887</identifier><identifier>PMID: 16676104</identifier><language>spa</language><publisher>Chile</publisher><subject>Adolescent ; Adult ; Antibodies, Monoclonal - therapeutic use ; Crohn Disease - drug therapy ; Female ; Gastrointestinal Agents - therapeutic use ; Humans ; Infliximab ; Male ; Middle Aged ; Retrospective Studies ; Severity of Illness Index ; Treatment Outcome</subject><ispartof>Revista medíca de Chile, 2006-03, Vol.134 (3), p.320-325</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16676104$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gellona V, José</creatorcontrib><creatorcontrib>Zarraonandia A, Antón</creatorcontrib><creatorcontrib>Zúñiga D, Alvaro</creatorcontrib><creatorcontrib>Palma C, Renato</creatorcontrib><creatorcontrib>Contreras P, Jaime</creatorcontrib><creatorcontrib>Silva Ch, Jaime</creatorcontrib><creatorcontrib>González D, Róbinson</creatorcontrib><creatorcontrib>Quintana V, Carlos</creatorcontrib><title>Infliximab in the treatment of patients with Crohn's disease: preliminary report</title><title>Revista medíca de Chile</title><addtitle>Rev Med Chil</addtitle><description>Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn's disease. Infliximab, a monoclonal antibody against tumor necrosis factor, is useful in the treatment of Crohn's disease, specially when the disease is active and associated to fistula formation.
To assess the effectiveness of Infliximab in patients with Crohn's disease.
Twelve patients with Crohn's disease (aged 16 to 63 years, 10 women) refractory to treatment with steroid, 5-aminosalicylic acid, antimicrobials and immunomodulatory drugs, were studied. A single intravenous 5 mg/kg dose Infliximab was administered. The Crohn's disease activity index (CDAI) was measured before and one week after the administration of the drug.
CDAI before and after Infliximab administration was 357+/-62 and 138+/-122 score points, respectively (p <0.005). According to this score, five patients had a severe and seven a moderate disease flare. The disease remitted in 7 (58%) and a clinical response was observed in 75%.
A single dose of Infliximab was effective to induce remission of the disease in 75% of this selected group of patients with Crohn's disease.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Crohn Disease - drug therapy</subject><subject>Female</subject><subject>Gastrointestinal Agents - therapeutic use</subject><subject>Humans</subject><subject>Infliximab</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Retrospective Studies</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><issn>0034-9887</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNo1kM1KxDAYRbNQnHH0FSQrXRWSNGkbd1L8GRjQha7L1_QLjfQnJik6b2_BcXXP4nDh3jOyZSyXma6qckMuY_xkTJQFry7IhhfFSkxuydt-soP7cSO01E009UhTQEgjTonOlnpIbsVIv13qaR3mfrqLtHMRIeI99QEHN7oJwpEG9HNIV-TcwhDx-pQ78vH0-F6_ZIfX5339cMg8z3XKqk6BMJaBlYKDAq01Y1pIBaoVSnQWhWFtBW1ZKZ3bQurOcGOtYp1pCzD5jtz-9fowfy0YUzO6aHAYYMJ5iU1Rasm5FKt4cxKXdsSu8WEdG47N_wf5LzecWGY</recordid><startdate>200603</startdate><enddate>200603</enddate><creator>Gellona V, José</creator><creator>Zarraonandia A, Antón</creator><creator>Zúñiga D, Alvaro</creator><creator>Palma C, Renato</creator><creator>Contreras P, Jaime</creator><creator>Silva Ch, Jaime</creator><creator>González D, Róbinson</creator><creator>Quintana V, Carlos</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200603</creationdate><title>Infliximab in the treatment of patients with Crohn's disease: preliminary report</title><author>Gellona V, José ; Zarraonandia A, Antón ; Zúñiga D, Alvaro ; Palma C, Renato ; Contreras P, Jaime ; Silva Ch, Jaime ; González D, Róbinson ; Quintana V, Carlos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p139t-8d5a2cf0af421a5a999009245a5b252dfe2c0b8ab78593f649dc1cff50dcb6ac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>spa</language><creationdate>2006</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Crohn Disease - drug therapy</topic><topic>Female</topic><topic>Gastrointestinal Agents - therapeutic use</topic><topic>Humans</topic><topic>Infliximab</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Retrospective Studies</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gellona V, José</creatorcontrib><creatorcontrib>Zarraonandia A, Antón</creatorcontrib><creatorcontrib>Zúñiga D, Alvaro</creatorcontrib><creatorcontrib>Palma C, Renato</creatorcontrib><creatorcontrib>Contreras P, Jaime</creatorcontrib><creatorcontrib>Silva Ch, Jaime</creatorcontrib><creatorcontrib>González D, Róbinson</creatorcontrib><creatorcontrib>Quintana V, Carlos</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Revista medíca de Chile</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gellona V, José</au><au>Zarraonandia A, Antón</au><au>Zúñiga D, Alvaro</au><au>Palma C, Renato</au><au>Contreras P, Jaime</au><au>Silva Ch, Jaime</au><au>González D, Róbinson</au><au>Quintana V, Carlos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Infliximab in the treatment of patients with Crohn's disease: preliminary report</atitle><jtitle>Revista medíca de Chile</jtitle><addtitle>Rev Med Chil</addtitle><date>2006-03</date><risdate>2006</risdate><volume>134</volume><issue>3</issue><spage>320</spage><epage>325</epage><pages>320-325</pages><issn>0034-9887</issn><abstract>Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn's disease. Infliximab, a monoclonal antibody against tumor necrosis factor, is useful in the treatment of Crohn's disease, specially when the disease is active and associated to fistula formation.
To assess the effectiveness of Infliximab in patients with Crohn's disease.
Twelve patients with Crohn's disease (aged 16 to 63 years, 10 women) refractory to treatment with steroid, 5-aminosalicylic acid, antimicrobials and immunomodulatory drugs, were studied. A single intravenous 5 mg/kg dose Infliximab was administered. The Crohn's disease activity index (CDAI) was measured before and one week after the administration of the drug.
CDAI before and after Infliximab administration was 357+/-62 and 138+/-122 score points, respectively (p <0.005). According to this score, five patients had a severe and seven a moderate disease flare. The disease remitted in 7 (58%) and a clinical response was observed in 75%.
A single dose of Infliximab was effective to induce remission of the disease in 75% of this selected group of patients with Crohn's disease.</abstract><cop>Chile</cop><pmid>16676104</pmid><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0034-9887 |
ispartof | Revista medíca de Chile, 2006-03, Vol.134 (3), p.320-325 |
issn | 0034-9887 |
language | spa |
recordid | cdi_proquest_miscellaneous_67941142 |
source | SciELO |
subjects | Adolescent Adult Antibodies, Monoclonal - therapeutic use Crohn Disease - drug therapy Female Gastrointestinal Agents - therapeutic use Humans Infliximab Male Middle Aged Retrospective Studies Severity of Illness Index Treatment Outcome |
title | Infliximab in the treatment of patients with Crohn's disease: preliminary report |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T12%3A02%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Infliximab%20in%20the%20treatment%20of%20patients%20with%20Crohn's%20disease:%20preliminary%20report&rft.jtitle=Revista%20med%C3%ADca%20de%20Chile&rft.au=Gellona%20V,%20Jos%C3%A9&rft.date=2006-03&rft.volume=134&rft.issue=3&rft.spage=320&rft.epage=325&rft.pages=320-325&rft.issn=0034-9887&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E67941142%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p139t-8d5a2cf0af421a5a999009245a5b252dfe2c0b8ab78593f649dc1cff50dcb6ac3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=67941142&rft_id=info:pmid/16676104&rfr_iscdi=true |